Bank of New York Mellon’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.23M | Buy |
108,209
+8,285
| +8% | +$256K | ﹤0.01% | 2540 |
|
|
2026
Q1 | $2.7M | Sell |
99,924
-8,342
| -8% | -$280K | ﹤0.01% | 2663 |
|
|
2025
Q4 | $4.64M | Buy |
108,266
+10,405
| +11% | +$392K | ﹤0.01% | 2366 |
|
|
2025
Q3 | $2.77M | Buy |
97,861
+4,826
| +5% | +$144K | ﹤0.01% | 2637 |
|
|
2025
Q2 | $1.74M | Buy |
93,035
+43,463
| +88% | +$824K | ﹤0.01% | 2818 |
|
|
2025
Q1 | $892K | Sell |
49,572
-623
| -1% | -$12.6K | ﹤0.01% | 3134 |
|
|
2024
Q4 | $844K | Buy |
50,195
+4,672
| +10% | +$89.6K | ﹤0.01% | 3254 |
|
|
2024
Q3 | $737K | Sell |
45,523
-13,976
| -23% | -$164K | ﹤0.01% | 3303 |
|
|
2024
Q2 | $489K | Buy |
59,499
+7,097
| +14% | +$74.3K | ﹤0.01% | 3597 |
|
|
2024
Q1 | $776K | Sell |
52,402
-4,193
| -7% | -$56.5K | ﹤0.01% | 3285 |
|
|
2023
Q4 | $821K | Buy |
56,595
+789
| +1% | +$8.07K | ﹤0.01% | 3294 |
|
|
2023
Q3 | $603K | Sell |
55,806
-1,018
| -2% | -$12.2K | ﹤0.01% | 3446 |
|
|
2023
Q2 | $733K | Buy |
56,824
+1,140
| +2% | +$15.4K | ﹤0.01% | 3388 |
|
|
2023
Q1 | $735K | Sell |
55,684
-781
| -1% | -$12.4K | ﹤0.01% | 3284 |
|
|
2022
Q4 | $847K | Sell |
56,465
-406
| -0.7% | -$3.72K | ﹤0.01% | 3275 |
|
|
2022
Q3 | $671K | Buy |
56,871
+4,510
| +9% | +$61K | ﹤0.01% | 3405 |
|
|
2022
Q2 | $592K | Sell |
52,361
-3,001
| -5% | -$60.3K | ﹤0.01% | 3486 |
|
|
2022
Q1 | $1.66M | Buy |
55,362
+145
| +0.3% | +$3.93K | ﹤0.01% | 3039 |
|
|
2021
Q4 | $1.46M | Buy |
55,217
+1,015
| +2% | +$30.6K | ﹤0.01% | 3169 |
|
|
2021
Q3 | $1.97M | Buy |
54,202
+3,008
| +6% | +$118K | ﹤0.01% | 2982 |
|
|
2021
Q2 | $2.22M | Sell |
51,194
-10,722
| -17% | -$405K | ﹤0.01% | 2917 |
|
|
2021
Q1 | $2.12M | Sell |
61,916
-5,080
| -8% | -$201K | ﹤0.01% | 2895 |
|
|
2020
Q4 | $2.34M | Sell |
66,996
-417
| -0.6% | -$12.1K | ﹤0.01% | 2755 |
|
|
2020
Q3 | $1.62M | Sell |
67,413
-1,135
| -2% | -$27.9K | ﹤0.01% | 2794 |
|
|
2020
Q2 | $1.25M | Sell |
68,548
-345
| -0.5% | -$6.21K | ﹤0.01% | 2968 |
|
|
2020
Q1 | $1.07M | Hold |
68,893
| – | – | ﹤0.01% | 2923 |
|
|
2019
Q4 | $1.47M | Buy |
68,893
+1,192
| +2% | +$24.5K | ﹤0.01% | 3019 |
|
|
2019
Q3 | $1.27M | Sell |
67,701
-3,753
| -5% | -$77.5K | ﹤0.01% | 3032 |
|
|
2019
Q2 | $1.86M | Sell |
71,454
-155
| -0.2% | -$3.5K | ﹤0.01% | 2828 |
|
|
2019
Q1 | $1.84M | Buy |
71,609
+61
| +0.1% | +$1.4K | ﹤0.01% | 2818 |
|
|
2018
Q4 | $1.65M | Buy |
71,548
+2,443
| +4% | +$68.9K | ﹤0.01% | 2834 |
|
|
2018
Q3 | $2.22M | Sell |
69,105
-5,527
| -7% | -$166K | ﹤0.01% | 2791 |
|
|
2018
Q2 | $2.11M | Sell |
74,632
-914
| -1% | -$32.5K | ﹤0.01% | 2817 |
|
|
2018
Q1 | $2.67M | Buy |
75,546
+650
| +0.9% | +$26K | ﹤0.01% | 2658 |
|
|
2017
Q4 | $2.9M | Buy |
74,896
+19,579
| +35% | +$745K | ﹤0.01% | 2629 |
|
|
2017
Q3 | $1.4M | Sell |
55,317
-235
| -0.4% | -$5.71K | ﹤0.01% | 3024 |
|
|
2017
Q2 | $1.52M | Sell |
55,552
-2,289
| -4% | -$62.6K | ﹤0.01% | 3005 |
|
|
2017
Q1 | $1.92M | Buy |
57,841
+13,116
| +29% | +$334K | ﹤0.01% | 2887 |
|
|
2016
Q4 | $1.06M | Buy |
44,725
+1,814
| +4% | +$52K | ﹤0.01% | 3224 |
|
|
2016
Q3 | $1.57M | Sell |
42,911
-766
| -2% | -$22K | ﹤0.01% | 2912 |
|
|
2016
Q2 | $974K | Sell |
43,677
-1,252
| -3% | -$31.1K | ﹤0.01% | 3154 |
|
|
2016
Q1 | $934K | Buy |
44,929
+2,334
| +5% | +$57.6K | ﹤0.01% | 3106 |
|
|
2015
Q4 | $1.29M | Sell |
42,595
-187
| -0.4% | -$5.67K | ﹤0.01% | 2999 |
|
|
2015
Q3 | $1.06M | Sell |
42,782
-8,188
| -16% | -$244K | ﹤0.01% | 3150 |
|
|
2015
Q2 | $1.64M | Buy |
50,970
+967
| +2% | +$36.9K | ﹤0.01% | 3049 |
|
|
2015
Q1 | $1.78M | Sell |
50,003
-3,809
| -7% | -$104K | ﹤0.01% | 2951 |
|
|
2014
Q4 | $1.22M | Buy |
53,812
+1,372
| +3% | +$27.7K | ﹤0.01% | 3173 |
|
|
2014
Q3 | $1.02M | Buy |
52,440
+4,913
| +10% | +$139K | ﹤0.01% | 3272 |
|
|
2014
Q2 | $1.73M | Sell |
47,527
-1,503
| -3% | -$51.1K | ﹤0.01% | 2987 |
|
|
2014
Q1 | $1.9M | Buy |
49,030
+4,359
| +10% | +$155K | ﹤0.01% | 2911 |
|
|
2013
Q4 | $1.27M | Buy |
44,671
+788
| +2% | +$23.1K | ﹤0.01% | 3154 |
|
|
2013
Q3 | $1.57M | Sell |
43,883
-1,427
| -3% | -$52.1K | ﹤0.01% | 2997 |
|
|
2013
Q2 | $1.51M | Buy |
+45,310
| New | +$2.05M | ﹤0.01% | 2943 |
|
Other funds holding RIGL
SCM
N
CP
RWM
HWAM
Bank of New York Mellon's RIGL Position: Q2 2026 in Review
Bank of New York Mellon increased its Rigel Pharmaceuticals (RIGL) stake by 8.3% in Q2 2026, buying an estimated $256K and bringing the position to 108,209 shares worth $4.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2540.
Bank of New York Mellon first reported a position in RIGL in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.64M in Q4 2025. 70 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.
- Bank of New York Mellon held 108,209 shares of Rigel Pharmaceuticals worth $4.23M as of Q2 2026.
- Bank of New York Mellon bought 8,285 Rigel Pharmaceuticals shares in Q2 2026, an estimated $256K.
- Rigel Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2540 holding.
- Bank of New York Mellon first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Rigel Pharmaceuticals position peaked at $4.64M in Q4 2025.
- 70 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.